104 related articles for article (PubMed ID: 17933133)
1. [Current status and future perspective of new drugs for hematological malignancies in Japan].
Ogura M
Rinsho Ketsueki; 2007 Oct; 48(10):1442-52. PubMed ID: 17933133
[No Abstract] [Full Text] [Related]
2. Leukemias and plasma cell myeloma.
Wiernik PH
Cancer Chemother Biol Response Modif; 1999; 18():268-92. PubMed ID: 10800488
[No Abstract] [Full Text] [Related]
3. A summer of hematologic science. Highlights from the 45th Annual Meeting of the American Society of Clinical Oncology, the 14th Congress of the European Hematology Association, and the 2009 Pan Pacific Lymphoma Conference.
Cheson BD; Ashforth E
Clin Adv Hematol Oncol; 2009 Sep; 7(9 Suppl 15):1-22; quiz 23-4. PubMed ID: 20102012
[No Abstract] [Full Text] [Related]
4. [Interferons in the treatment of hematological diseases].
Jantunen E; Nousiainen T
Duodecim; 1998; 114(12):1240-7. PubMed ID: 11524770
[No Abstract] [Full Text] [Related]
5. Topoisomerase I inhibitors in the treatment of myelodysplastic syndromes and chronic myelomonocytic leukemia.
Beran M
Leuk Res; 2004 May; 28(5):443-6. PubMed ID: 15068895
[No Abstract] [Full Text] [Related]
6. 2nd International Congress on Leukemia, Lymphoma and Myeloma.
Arat M; Ozsan GH; Yenerel MN; Cetin M; Ozcan M
Expert Rev Hematol; 2009 Oct; 2(5):509-12. PubMed ID: 21083016
[TBL] [Abstract][Full Text] [Related]
7. [Home care of hematological malignancies].
Urabe A
Gan To Kagaku Ryoho; 2006 May; 33(5):599-601. PubMed ID: 16685155
[TBL] [Abstract][Full Text] [Related]
8. Chronic myelomonocytic leukemia with overlap dysplastic/proliferative presentation.
Gologan R; Stoia R; Radulescu I; Georgescu D; Ostroveanu D
Leuk Res; 2007 Jun; 31(6):878-9. PubMed ID: 16956659
[No Abstract] [Full Text] [Related]
9. [Programs for continuing medical education: B session 7. Progress in treatment for hematologic diseases].
Higashihara M
Nihon Naika Gakkai Zasshi; 2014 Mar; 103(3):717-23. PubMed ID: 24796142
[No Abstract] [Full Text] [Related]
10. Battling the hematological malignancies: the 200 years' war.
Lichtman MA
Oncologist; 2008 Feb; 13(2):126-38. PubMed ID: 18305057
[TBL] [Abstract][Full Text] [Related]
11. New drugs for the treatment of lymphoma.
Paoluzzi L; Kitagawa Y; Kalac M; Zain J; O'Connor OA
Hematol Oncol Clin North Am; 2008 Oct; 22(5):1007-35, x. PubMed ID: 18954749
[TBL] [Abstract][Full Text] [Related]
12. Is there an entity of chemically induced BCR-ABL-positive chronic myelogenous leukemia?
Lichtman MA
Oncologist; 2008 Jun; 13(6):645-54. PubMed ID: 18586919
[TBL] [Abstract][Full Text] [Related]
13. Multiple myeloma developing after imatinib mesylate therapy for chronic myeloid leukemia.
Galanopoulos A; Papadhimitriou SI; Kritikou-Griva E; Georgiakaki M; Anagnostopoulos NI
Ann Hematol; 2009 Mar; 88(3):281-2. PubMed ID: 18726593
[No Abstract] [Full Text] [Related]
14. BCR-ABL positive chronic myeloid leukemia with concurrent JAK2(V617F) positive myelodysplastic syndrome/myeloproliferative neoplasm (RARS-T).
Gattenlohner S; Völker HU; Etschmann B; Einsele H; Müller-Hermelink HK
Am J Hematol; 2009 May; 84(5):306-7. PubMed ID: 18951468
[No Abstract] [Full Text] [Related]
15. [Double cancer in elderly patients with hematologic malignancies].
Niitsu N; Umeda M
Nihon Ronen Igakkai Zasshi; 1996 Apr; 33(4):269-72. PubMed ID: 8752714
[TBL] [Abstract][Full Text] [Related]
16. [Advances in the target therapy of hematological malignancies].
Niu T; Liu T
Sichuan Da Xue Xue Bao Yi Xue Ban; 2014 Jul; 45(4):642-6. PubMed ID: 25286692
[TBL] [Abstract][Full Text] [Related]
17. Optimizing outcomes for patients with advanced disease in chronic myelogenous leukemia.
Giles FJ; DeAngelo DJ; Baccarani M; Deininger M; Guilhot F; Hughes T; Mauro M; Radich J; Ottmann O; Cortes J
Semin Oncol; 2008 Feb; 35(1 Suppl 1):S1-17; quiz S18-20. PubMed ID: 18346528
[TBL] [Abstract][Full Text] [Related]
18. Coexistence of multiple myeloma and chronic myelogenous leukemia.
Tanaka M; Tanaka K; Oizumi K
Int J Hematol; 1999 Aug; 70(2):132-3. PubMed ID: 10497853
[No Abstract] [Full Text] [Related]
19. Extramedullary disease and targeted therapies for hematological malignancies--is the association real?
Raanani P; Shpilberg O; Ben-Bassat I
Ann Oncol; 2007 Jan; 18(1):7-12. PubMed ID: 16790518
[TBL] [Abstract][Full Text] [Related]
20. Chronic myelogenous leukemia with the e6a2 BCR-ABL and lacking imatinib response: presentation of two cases.
Vefring HK; Gruber FX; Wee L; Hovland R; Hjorth-Hansen H; Gedde Dahl T; Meyer P
Acta Haematol; 2009; 122(1):11-6. PubMed ID: 19641300
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
